WHO ICTRP trial
A study of PRS-344/S095012 (PD-L1x4-1BB bispecific antibody) in patients with…
EUCTR2019-003456-36-BE · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2019-003456-36-BE |
|---|---|
| Public title | A study of PRS-344/S095012 (PD-L1x4-1BB bispecific antibody) in patients with solid tumors |
| Scientific title | A first in human Phase 1/2 open-label, multicenter, dose escalation and expansion study of PRS-344/S095012 in patients with solid tumors |
| Primary sponsor | Institut de Recherches Internationales Servier |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): yes Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Belgium;United States;Brazil;Australia;France;Switzerland;Spain |
| Conditions | Advanced and/or metastatic solid tumors MedDRA version: 21.1 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Product Name: S095012 Product Code: S095012 Pharmaceutical Form: Concentrate for solution for infusion Current Sponsor code: S095012 Other descriptive name: PRS-344 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal… |
| Registration date | Oct 6, 2021 |
| Target size | 277 |
| Secondary IDs | CL1-95012-001 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: